KPRX
Kiora Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.53M
P/E Ratio
—
EPS
$-2.64
Beta
-0.77
52W High
$4.18
52W Low
$1.76
50-Day MA
$2.09
200-Day MA
$2.40
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
2.41
PEG Ratio
—
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for ocular diseases and neurodegenerative disorders. With a pipeline of novel drug candidates addressing significant unmet medical needs, Kiora leverages its specialized expertise in drug formulation and delivery systems to advance its clinical studies towards regulatory approval. The company’s commitment to enhancing patient outcomes, supported by robust research capabilities and strategic partnerships, positions it favorably within the biopharmaceutical landscape and makes it an attractive opportunity for institutional investors looking to invest in cutting-edge therapeutics.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-3.71M |
| EBITDA | $-9.43M |
| Operating Margin | 0.00% |
| Return on Equity | -51.70% |
| Return on Assets | -19.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.29 |
| Price-to-Book | 0.47 |
| Price-to-Sales (TTM) | 0.14 |
| EV/Revenue | 13.31 |
| EV/EBITDA | -1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.95M |
| Float | $3.82M |
| % Insiders | 3.42% |
| % Institutions | 20.53% |
Analyst Ratings
Consensus ($12.00 target)
1
Strong BuyData last updated: 4/8/2026